NOVEL PHARMA
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
NOVEL PHARMA - overview
Established
2017
Location
Seoul, -, South Korea
Primary Industry
Pharmaceuticals
About
Based in Seoul, South Korea, founded in 2017, Novel Pharma Inc. trading under the name NOVEL PHARMA, operates as a biotechnology company that focuses on creating treatments for rare diseases, especially rare pediatric lysosomal storage disorders, and is known for its developments including Hunterase IV-ERT and ICV-ERT for Hunter syndrome.
Primary Industry
Pharmaceuticals
Sub Industries
Biopharmaceuticals, Biotechnology, Therapeutic Devices, Specialty Pharmaceuticals, Pharmaceuticals, Pharmaceutical Research & Development
Website
www.novelp.com/
Verticals
HealthTech
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.